Arcturus Therapeutics Holdings Inc.
ARCT
$10.53
$0.232.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.77M | 41.67M | 49.86M | 38.01M | 30.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.77M | 41.67M | 49.86M | 38.01M | 30.86M |
| Cost of Revenue | 43.78M | 39.13M | 4.38M | 52.77M | 36.62M |
| Gross Profit | -21.01M | 2.54M | 45.48M | -14.76M | -5.77M |
| SG&A Expenses | 12.38M | 13.28M | 12.32M | 14.85M | 12.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.16M | 52.41M | 70.99M | 67.62M | 49.13M |
| Operating Income | -33.39M | -10.74M | -21.13M | -29.61M | -18.27M |
| Income Before Tax | -30.01M | -7.12M | -17.37M | -26.45M | -11.45M |
| Income Tax Expenses | -4.00K | -217.00K | -150.00K | 368.00K | 262.00K |
| Earnings from Continuing Operations | -30.01M | -6.90M | -17.22M | -26.82M | -11.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.01M | -6.90M | -17.22M | -26.82M | -11.71M |
| EBIT | -33.39M | -10.74M | -21.13M | -29.61M | -18.27M |
| EBITDA | -32.58M | -9.83M | -20.22M | -28.71M | -17.46M |
| EPS Basic | -1.11 | -0.26 | -0.64 | -1.00 | -0.44 |
| Normalized Basic EPS | -0.69 | -0.16 | -0.40 | -0.60 | -0.27 |
| EPS Diluted | -1.11 | -0.26 | -0.64 | -1.00 | -0.44 |
| Normalized Diluted EPS | -0.69 | -0.16 | -0.40 | -0.60 | -0.27 |
| Average Basic Shares Outstanding | 27.00M | 27.06M | 26.97M | 26.88M | 26.63M |
| Average Diluted Shares Outstanding | 27.00M | 27.06M | 26.97M | 26.88M | 26.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |